The Cancer Letter

Inside information on cancer research and drug development

Clinical Roundup

Vectibix superior to bevacizumab in Japanese patients with wild-type RAS mCRC

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print
BYLINE
IN THIS ISSUE
DOWNLOAD PDFTABLE OF CONTENTS

Data from the phase III PARADIGM clinical trial of Vectibix (panitumumab) in Japanese patients with previously untreated unresectable wild-type RAS metastatic colorectal cancer were featured during the plenary session of the 2022 ASCO annual meeting. 

To access this subscriber-only content please log in or subscribe.

If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.

Login Subscribe
Table of Contents

YOU MAY BE INTERESTED IN

Clinical Roundup

Dual-targeted therapies + chemo shows high response rates in BRAF-mutated metastatic CRC, phase III trial shows

Patients with metastatic colorectal cancer harboring BRAF V600E mutations benefitted from first-line treatment with the targeted therapies Braftovi(encorafenib) and Erbitux(cetuximab) plus a mFOLFOX6 chemotherapy regimen, according to results from the phase III BREAKWATER trial led by researchers at the University of Texas MD Anderson Cancer Center.
Table of Contents

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login

Site license subscribers:
Log in with your IP | Register a sponsored account